Results 121 to 130 of about 7,735 (172)
, 2012 Ola E Dahl1,21Department of Orthopaedics, Innlandet Hospital Trust, Elverum Central Hospital, Elverum, Norway; 2Thrombosis Research Institute, London, UKAbstract: Venous thromboembolism, presenting as deep vein thrombosis or pulmonary embolism, is a ...
Dahl OE
core
DABIGATRAN ACYLGLUCURONIDE, THE MAJOR HUMAN METABOLITE OF DABIGATRAN:
Abstracts of Annual meeting of Japanese Society for the Study of Xenobiotics, 2010 Ebner, Thomas +2 more
openaire +1 more source
Dabigatran Acylglucuronide, the Major Metabolite of Dabigatran, Shows a Weaker Anticoagulant Effect than Dabigatran [PDF]
Pharmaceutics, 2022 Dabigatran (DAB) is an orally administered thrombin inhibitor. Both DAB and its main metabolite dabigatran acylglucuronide (DABG) have established anticoagulant effects. Here, we aimed to compare the relative anticoagulant effects of DABG and DAB in humans.
Jin-Woo Park +2 more
exaly +4 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
BMJ, 2014
Doctors and patients must tread carefully through emerging risks Options for stroke prevention in high risk non-valvular atrial fibrillation have recently broadened with the addition of new oral anticoagulants as an alternative to warfarin, the traditional and effective treatment.
Blake, Charlton, Rita, Redberg
openaire +2 more sources
Doctors and patients must tread carefully through emerging risks Options for stroke prevention in high risk non-valvular atrial fibrillation have recently broadened with the addition of new oral anticoagulants as an alternative to warfarin, the traditional and effective treatment.
Blake, Charlton, Rita, Redberg
openaire +2 more sources
2023
Abstract Dabigatran is a direct oral anticoagulant that acts through specific and reversible inhibition of thrombin. It has been developed as a fixed-dose, modern alternative to vitamin K antagonists such as warfarin. Dabigatran does not require frequent blood testing or dose adjustments.
Alexander P. Benz, Stefan H. Hohnloser
openaire +1 more source
Abstract Dabigatran is a direct oral anticoagulant that acts through specific and reversible inhibition of thrombin. It has been developed as a fixed-dose, modern alternative to vitamin K antagonists such as warfarin. Dabigatran does not require frequent blood testing or dose adjustments.
Alexander P. Benz, Stefan H. Hohnloser
openaire +1 more source
Drugs, 2008
Dabigatran etexilate is an orally administered prodrug of dabigatran, which is a potent, concentration-dependent inhibitor of thrombus formation and thrombin-induced platelet aggregation. Dabigatran etexilate pharmacokinetics were linear across a wide dosage range.
Mark, Sanford, Greg L, Plosker
openaire +2 more sources
Dabigatran etexilate is an orally administered prodrug of dabigatran, which is a potent, concentration-dependent inhibitor of thrombus formation and thrombin-induced platelet aggregation. Dabigatran etexilate pharmacokinetics were linear across a wide dosage range.
Mark, Sanford, Greg L, Plosker
openaire +2 more sources
Pharmacogenetics of dabigatran etexilate interindividual variability [PDF]
Thrombosis Research, 2016 Introduction Dabigatran etexilate is given in fixed doses without coagulation monitoring for the prevention of blood clots in at risk adults. A high inter-individual variability in blood concentrations of the active metabolite of dabigatran has been ...
Maurizio Margaglione +2 more
exaly +2 more sources
Removal of Dabigatran by Hemodialysis
American Journal of Kidney Diseases, 2013Dabigatran is a newly available oral direct thrombin inhibitor approved for anticoagulation therapy to prevent strokes in patients with nonvalvular atrial fibrillation. Unlike warfarin, dabigatran's observed therapeutic window and minimal drug-to-drug interaction suggest that invasive laboratory testing and dose adjustment is not necessary.
William E Dager
exaly +3 more sources